Tonix Pharmaceuticals Holding (TNXP) said Friday it received a patent from the US Patent and Trademark Office for its pre-filled autoinjector comprising of Zembrace SymTouch composition to treat migraines.
The patent is anticipated to expire in 2036, excluding potential extensions, the biopharmaceutical company added.
Zembrace is a US Food and Drug Administration-approved treatment for migraines, Tonix said.
Shares of the company rose 23% in recent Friday premarket activity.
Price: 0.1685, Change: +0.03, Percent Change: +23.35
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。